P1457: DEMOGRAPHICS AND TREATMENT OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH OFF-THE-SHELF EBV-SPECIFIC CTL (TABELECLEUCEL) UNDER AN ONGOING EXPANDED ACCESS PROGRAM IN EUROPE: FIRST ANALYSES

• S. Choquet,
• B. Uttenthal,
• S. Chaganti,
• P. Comoli,
• R. Trappe,
• A. Friedetzky,
• B. Xing,
• X. Li,
• T. Polak,
• L. Gamelin,
• J.-H. Terwey,
• D. Dierickx

Affiliations

S. Choquet

1 Hématologie clinique, Sorbonne Université, Hôpital de la Pitié-Salpêtrière, Paris, France

B. Uttenthal

2 Department of Haematology, Cambridge University Teaching Hospitals NHS Foundation Trust, Cambridge

S. Chaganti

3 Department of Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom

P. Comoli

4 Cell Factory and Pediatric Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

R. Trappe

5 DIAKO Evangelisches Diakonie-Krankenhaus Bremen, Bremen, Germany

A. Friedetzky

6 Atara Biotherapeutics, Zug, Switzerland

B. Xing

7 Atara Biotherapeutics, Thousand Oaks, United States of America

X. Li

7 Atara Biotherapeutics, Thousand Oaks, United States of America

T. Polak

8 Biostatistics & Epidemiology, ErasmusMC, Rotterdam

L. Gamelin

7 Atara Biotherapeutics, Thousand Oaks, United States of America

J.-H. Terwey

6 Atara Biotherapeutics, Zug, Switzerland

D. Dierickx

10 Department of Hematology, University Hospital Leuven, Leuven, Belgium